The Gene 60% of Americans Carry (That Most Doctors Ignore)
MTHFR variants reduce your ability to convert folic acid into usable folate. Up to 60% of the population has one. Most have never been tested.
MTHFR. It looks like an abbreviation someone typed while frustrated. It stands for methylenetetrahydrofolate reductase, which is worse.
But what it does is simple. MTHFR is the enzyme that performs the final step in converting folic acid into 5-MTHF, the form of folate your cells can actually use. Every step in the conversion pathway matters, but this is the bottleneck. This is where the assembly line from Part 2 either finishes the product or lets it back up.
And in up to 60% of the U.S. population, this enzyme doesn't work at full capacity. Not because it's broken. Because the gene that codes for it has a variant.
Two Variants, Different Severities
The MTHFR gene has two common variants that affect enzyme function: C677T and A1298C. You get one copy of the gene from each parent, so you can carry zero, one, or two copies of either variant.
C677T is the most studied. If you're heterozygous (one copy, written CT), your MTHFR enzyme runs at roughly 35% reduced efficiency. If you're homozygous (two copies, TT), it drops to approximately 70% reduced activity.
That's not a subtle difference. That's the last machine on your folate assembly line running at 30% of its designed speed.
A1298C is less severe. Homozygous (two copies) reduces enzyme activity by about 30-40%. You can also carry one copy of each variant (compound heterozygous), which creates its own reduction in function that researchers are still quantifying.
The CDC acknowledges all of this directly. Their position: people with MTHFR variants can still process folic acid, just less efficiently. Those with the TT genotype have average blood folate levels about 16% lower than those with the normal CC genotype when consuming the same amount of folic acid.
16% lower. Same intake. Same food. Different genetics.
How Common Is This?
More common than you'd think. More common than most doctors act like it is.
CDC data indicates up to 60% of the U.S. population carries at least one MTHFR variant. That's not a rare genetic condition. That's the majority.
The distribution isn't even across ethnic groups. For the C677T homozygous variant (TT), the most functionally impaired version: approximately 10-12% of people of European descent carry it. Among Hispanic and Mexican-descent populations, that jumps to 20-25%. Among people of African descent, it's much lower at 1-4%.
de Góes Soligo and colleagues found the C677T variant present in 49.2% of fertile women and 58.5% of infertile women in their study population. That's not proof that MTHFR causes infertility. But it's a correlation that warrants attention, especially when you consider that folate is critical for cell division and DNA synthesis. The exact processes that reproduction depends on.
The Controversy
This is where it gets messy.
On one side, you have functional medicine practitioners who treat MTHFR variants like the explanation for everything. Depression, anxiety, chronic fatigue, infertility, autoimmunity. Got an MTHFR variant? That's your problem. Take methylfolate. Problem solved.
On the other side, you have mainstream medicine largely dismissing MTHFR testing as unnecessary. The American College of Medical Genetics doesn't recommend routine testing. Many insurance plans won't cover it. Some doctors will actively discourage patients from getting tested, arguing that the clinical significance is overstated.
Both sides are partially right and partially full of it.
The functional medicine crowd overclaims. Having an MTHFR variant doesn't automatically mean you're sick or deficient. The CDC is clear on this: most people with variants process enough folic acid to avoid clinical deficiency. The 16% reduction in blood folate for TT carriers is real but modest. Not everyone with a variant has symptoms. Not every symptom traces back to methylation.
But the mainstream dismissal is its own kind of problem. When 60% of the population carries a variant that reduces the efficiency of a critical metabolic enzyme, and the food supply is built around the synthetic substrate for that exact enzyme, and most people never get tested? That's not an overclaiming problem. That's an underclaiming problem.
A 16% reduction in blood folate sounds manageable in isolation. But folate doesn't work in isolation. It feeds the methylation cycle. That cycle produces SAMe, which is the primary methyl donor your body uses for DNA repair, neurotransmitter synthesis, and detoxification. Miller's 2008 review in Alternative Medicine Review traced how disrupted folate metabolism cascades into impaired serotonin, dopamine, and norepinephrine production. Bhatia and Singh's 2015 paper in Fundamental & Clinical Pharmacology connected the resulting homocysteine elevation to direct neurotoxicity.
A 16% reduction at the input creates a larger-than-16% problem at the output. Especially over years. Especially in a population that's simultaneously accumulating unmetabolized folic acid that may be competing with whatever functional folate they do produce.
The Testing Gap
A standard metabolic panel doesn't check MTHFR status. Neither does a CBC. Neither does a basic vitamin panel. You can get a genetic test through companies like 23andMe or through a simple blood test ordered by a doctor who knows what to ask for. But if your doctor doesn't think MTHFR matters, they won't order it. And if your insurance doesn't cover it, you're paying out of pocket for information about your own genome.
60% of the population carries these variants. The food supply is designed around a synthetic vitamin that these variants make harder to process. And testing is treated as optional, fringe, or unnecessary.
That's the gap. Not just in methylation. In the conversation itself.
This is Part 3 of The Methylation Gap series. Previously: Your Body Can't Use the Vitamin In Your Bread.
Sources
- CDC: MTHFR Gene Variant and Folic Acid Facts (opens in new tab)
- Miller AL. "The methylation, neurotransmitter, and antioxidant connections between folate and depression" (2008, Alternative Medicine Review) (opens in new tab)
- Bhatia P, Singh N. "Homocysteine excess: delineating the possible mechanism of neurotoxicity and depression" (2015, Fundamental & Clinical Pharmacology) (opens in new tab)
- Adverse Effects of Excessive Folic Acid (2025, PMC) (opens in new tab)
